论文部分内容阅读
目的:分析阿昔洛韦和更昔洛韦对水痘患者抗水痘-带状疱疹病毒的临床疗效。方法:应用计算机检索PUBMED、MEDLINE、EMBASE、CNKI、VIP和万方数据库,查找和比较阿昔洛韦、更昔洛韦治疗水痘患者的随机对照试验结果,检索时间均为建库至2017年5月31日止;手工检索、下载、阅读、评价纳入文献的参考文献;按纳入和排除标准确定是否进入研究,由2人独立进行纳入文献的筛选和质量评价,采用Rev Man 5.3版统计学软件进行Meta分析。结果:纳入13篇研究文献,共1 691例患者(更昔洛韦组920例,阿昔洛韦组771例),结果显示治疗水痘患者的总有效率(Ζ=5.47,P<0.01)以及疼痛消失时间(Ζ=11.85,P<0.01)、体温复常时间(Ζ=3.35,P<0.01)和结痂时间(Ζ=5.23,P<0.01)方面,经两组间比较其差异均有统计学意义;不良反应方面仅有3篇研究文献有比较,所有不良反应均较为轻微,经两组间比较其差异均无统计学意义(Ζ=1.24,P>0.05)。结论:更昔洛韦和阿昔洛韦均有显著的抗水痘病毒作用,更昔洛韦在有效率、疼痛缓解时间、体温复常时间、结痂时间等方面均更有优势;二者不良反应均较为轻微,相互比较无差异。
Objective: To analyze the clinical efficacy of acyclovir and ganciclovir in the treatment of varicella-zoster virus in chickenpox patients. Methods: The randomized controlled trials of acyclovir and ganciclovir in patients with chickenpox were searched and searched by PUBMED, MEDLINE, EMBASE, CNKI, VIP and Wanfang database. The retrieval time was from 5 to 5 years Month 31st; Manually search, download, read and evaluate references included in the literature; Determine whether to enter the study according to the inclusion and exclusion criteria, independently screened and quality evaluated by 2 persons, and use RevMan version 5.3 statistical software Meta-analysis. RESULTS: A total of 1 691 patients (920 in the ganciclovir group and 771 in the acyclovir group) were included in the 13 studies and the results showed that the total effective rate (Z = 5.47, P <0.01) for the treatment of chickenpox patients and Pain disappear time (Z = 11.85, P <0.01), body temperature normalization time (Z = 3.35, P <0.01) and scab time (Z = 5.23, P <0.01) Statistical significance; Adverse reactions only three studies have compared the literature, all the adverse reactions were mild, no significant difference between the two groups (Z = 1.24, P> 0.05). Conclusion: Both ganciclovir and acyclovir have significant anti-varicella virus effect. Ganciclovir has more advantages in efficiency, pain relief time, body temperature recovery time and scab time. The responses were all mild with no difference compared to each other.